Vaxcyte, Inc. (PCVX) News
Follow Vaxcyte, Inc. (PCVX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Vaxcyte Price Target Cut to $130.00/Share From $133.00 by B of A Securities
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 05:33 PM UTC
L
Vaxcyte Price Target Maintained With a $110.00/Share by Needham
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 10:25 AM UTC
M
PCVX to release OPUS-1 phase III data for VAX-31 by end-October
Vaxcyte said OPUS-1 phase III data for VAX-31 will target broader pneumococcal coverage and an improved immune response and is due for release by end of October.
EQUITY | Sep 09, 2026, 08:07 PM UTC
L
PCVX VAX-31 phase III data expected by end of October
OPUS-1 phase III data for VAX-31 are expected to be released by end of October. The company says commercial and manufacturing infrastructure is in place, with pediatric and Group A strep programs advancing.
EQUITY | Sep 09, 2026, 07:40 PM UTC
L
PCVX VAX-31 targets dominant pneumococcal market share
PCVX said its VAX-31 aims for dominant market share with broader pneumococcal vaccine coverage. The company expects pivotal phase III data for VAX-31 by October.
EQUITY | Sep 08, 2026, 08:16 PM UTC
L
Vaxcyte names David McAvoy chief legal and compliance officer
Vaxcyte appointed David McAvoy as chief legal officer, chief compliance officer and corporate secretary, while Mikhail Eydelman remains senior vice president and general counsel.
REGULATION | Sep 03, 2026, 08:42 PM UTC
L
Vaxcyte names Chief Medical Officer, Chief Legal Officer; narrows VAX-31 OPUS-1 topline guidance
Vaxcyte appointed a Chief Medical Officer and a Chief Legal Officer, and narrowed guidance for expected VAX-31 OPUS-1 topline data (initial high-level study results).
EQUITY | Sep 03, 2026, 08:12 PM UTC
L
unresolved to participate in upcoming investor conferences
unresolved said it will participate in upcoming investor conferences.
EQUITY | Aug 27, 2026, 08:07 PM UTC
L
PCVX - Vaxcyte to Participate in Upcoming Investor Conferences
PCVX - Vaxcyte to Participate in Upcoming Investor Conferences
EQUITY | Aug 27, 2026, 08:05 PM UTC
L
PCVX - Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
PCVX - Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 05, 2026, 08:05 PM UTC
L
PCVX Maintain Buy, $116 PT – now is the time to understand VAX-A1 @ GUGG
PCVX Maintain Buy, $116 PT – now is the time to understand VAX-A1 @ GUGG
EQUITY | Jul 14, 2026, 01:11 PM UTC